251 related articles for article (PubMed ID: 17158545)
21. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
22. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
23. Identification of novel VHL targets that are associated with the development of renal cell carcinoma.
Abdulrahman M; Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Wiesener MS; Richards FM; Johnson CM; Latif F; Maher ER
Oncogene; 2007 Mar; 26(11):1661-72. PubMed ID: 17001320
[TBL] [Abstract][Full Text] [Related]
24. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
[TBL] [Abstract][Full Text] [Related]
25. Renal cell carcinoma development and miRNAs: a possible link to the EGFR pathway.
Dias F; Teixeira AL; Santos JI; Gomes M; Nogueira A; Assis J; Medeiros R
Pharmacogenomics; 2013 Nov; 14(14):1793-803. PubMed ID: 24192126
[TBL] [Abstract][Full Text] [Related]
26. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
27. Identification of novel VHL target genes and relationship to hypoxic response pathways.
Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER
Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735
[TBL] [Abstract][Full Text] [Related]
28. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
29. From molecular understanding to clinical advances.
Lee CH; Motzer RJ
Nat Rev Urol; 2014 Feb; 11(2):77-9. PubMed ID: 24366347
[TBL] [Abstract][Full Text] [Related]
30. The molecular biology of renal cell carcinoma.
Keefe SM; Nathanson KL; Rathmell WK
Semin Oncol; 2013 Aug; 40(4):421-8. PubMed ID: 23972705
[TBL] [Abstract][Full Text] [Related]
31. Familial renal cell carcinoma from the Swedish Family-Cancer Database.
Liu H; Sundquist J; Hemminki K
Eur Urol; 2011 Nov; 60(5):987-93. PubMed ID: 21621909
[TBL] [Abstract][Full Text] [Related]
32. The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation.
Lovell M; Lott ST; Wong P; El-Naggar A; Tucker S; Killary AM
Cancer Res; 1999 May; 59(9):2182-9. PubMed ID: 10232606
[TBL] [Abstract][Full Text] [Related]
33. The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-kappaB-dependent antiapoptotic pathway.
Qi H; Ohh M
Cancer Res; 2003 Nov; 63(21):7076-80. PubMed ID: 14612498
[TBL] [Abstract][Full Text] [Related]
34. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting.
Haase VH
Semin Cell Dev Biol; 2005; 16(4-5):564-74. PubMed ID: 15908240
[TBL] [Abstract][Full Text] [Related]
35. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
36. Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer.
Schmid V; Lafleur VN; Lombardi O; Li R; Salama R; Colli L; Choudhry H; Chanock S; Ratcliffe PJ; Mole DR
Sci Rep; 2019 Dec; 9(1):18768. PubMed ID: 31822727
[TBL] [Abstract][Full Text] [Related]
37. [50 years of renal cell carcinoma].
Doehn C
Aktuelle Urol; 2019 Aug; 50(4):378-385. PubMed ID: 31398756
[TBL] [Abstract][Full Text] [Related]
38. MicroRNAs: exploring a new dimension in the pathogenesis of kidney cancer.
White NM; Yousef GM
BMC Med; 2010 Oct; 8():65. PubMed ID: 20964839
[TBL] [Abstract][Full Text] [Related]
39. Kidney cancer: identification of novel targets for therapy.
Weiss RH; Lin PY
Kidney Int; 2006 Jan; 69(2):224-32. PubMed ID: 16408110
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
